2. University Hospitals of Leicester, University of Leicester, Leicester Biomedical Research Centre, Leicester, United Kingdom
3. Imperial College of Science, Technology and Medicine, London, United Kingdom
4. NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
5. Ramsay Générale de Santé, Hopital Privé Jacques Cartier, Massy, France
6. Abbott Vascular, Inc., Santa Clara, CA, USA
7. Centre Hospitalier de l’Université de Montréal and Hôpital Hôtel-Dieu de Montréal, Montreal, Quebec, Canada
8. University Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
9. Department of Surgery, UH Cleveland Medical Center, Cleveland, Ohio, USA
10. Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands
11. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Methods and results: Patients with distal LM bifurcation disease randomized to PCI with everolimus-eluting stents in the EXCEL trial were categorized into those with and without trifurcation involvement. Angiographic and procedural characteristics in addition to clinical events through 5-year follow-up after PCI were compared. Among 605 patients with site-reported distal LM disease, 61 patients (10.1%) were identified with trifurcation anatomy. The 5-year primary composite endpoint of death, myocardial infarction, or stroke occurred in 16.6% of patients with trifurcation disease compared with 22.5% of patients with distal bifurcation disease only (p=0.32). Ischemia-driven target lesion revascularization rates were also similar (11.9% versus 12.0%, p=0.94). No significant differences in definite or probable stent thrombosis were observed between treatment groups (1.7% versus 2.3%, p=0.76).
Conclusions: Despite the greater inherent complexity, procedural and long-term clinical outcomes following PCI of distal LM trifurcations with everolimus-eluting stents in a modest-sized cohort from the EXCEL trial were similar compared with treatment of distal LM bifurcation disease without trifurcations. These findings support PCI as a treatment strategy for selected patients with distal LM trifurcation disease.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com